Thursday, 3 July 2014

A deal inked between Sysmex and Bayer

Sysmex and Bayer inked a deal that made customized drug yet an alternate stride forward. The Japanese diagnostics titan and the German drugmaker will create companion diagnostic tests intended for focused cancer treatment.

Not, one or the other side is uncovering budgetary subtle elements, however they'll bring out their understanding through subsidiaries. The arrangement is to match blood-based partner symptomatic tests created by Sysmex's recently gained Inostics division with focused anti-cancer drugs advanced by Bayer HealthCare.

Their organization will depend vigorously on Sysmex Inostics' Beaming innovation, which empowers to a great degree sensitive diagnostics tests that can screen for circling tumor DNA push off into the circulation system in a procedure known as a "fluid biopsy." It's intended to be a non-intrusive option to routine biopsies, where a bit of a tumor must be uprooted and tried. Sysmex grabbed up Inostics in late September, which had been possessed by Germany's Indivumed and has operations in Hamburg, Germany and Baltimore, MD.

"Blood-based DNA tests provide diagnostics options for cancer patients without tumor biopsies being necessary," noted Andreas Busch, head of Global Drug Discovery and member of Bayer HealthCare's Executive Committee, in a statement. "With this collaboration, we continue to strengthen our engagement in the field of personalized medicine with the aim of developing innovative therapies for cancer patients."

Likewise, companion diagnostics are presently a a usual part of drug advancement. The companion diagnostic is intended to help detect a specific transformation or hereditary quality that would chalk out patients who react best to a given medication. What's more Sysmex is wagering its manage Bayer will fuel significant growth for the organization in the partner diagnostics space.

Hence, companion diagnostic market is growing fast and its benefits are being recognized globally. A latest report shows that Companion Diagnostic market would reach a value of $3.5 billion by 2020. It would be interesting to watch the future developments of the market.

Philips and Salesforce inks a deal

There's more where that originated from. Salesforce and Philips have reported a vital association to convey a more collective healthcare framework.

In a media roundtable , the organizations uncovered two clinical applications which have as of now been made and will be accessible on the stage this hot time of year. Philips ecarecoordinator and Philips ecarecompanion will sit nearby Philips' Hospital to Home telehealth operation, enhancing what the social insurance supplier calls an "emergency" today, with in excess of 171 million individuals anticipated that will be existing with endless conditions in the US by 2030.

The result, clearly, is more noteworthy transparency and correspondence in the middle of patients and human services suppliers, with the two organizations plotting a future whereby applications will be fundamental to social insurance, from planning toward oneself and aversion to finding and medicine.

“We have entered a new transformative era for healthcare, and technology is enabling the industry to connect to, care for and engage with patients and each other in a profound new way,” said Salesforce CEO Benioff.

Salesforce included that through the open Salesforce1 stage, designers and Isvs will have the capacity to work together and construct their health awareness results, refering to Apple's Healthkit as a comparable player.

It's obviously been an occupied couple of months at Salesforce towers, with the dispatch of a UK server farm and the renaming of the Heron Tower as the Salesforce Tower, with the current stress based upon the 'Web of Customers' and the dispatch of the Salesforce1 application.

This most recent play obviously puts that on the guide, imagining a positively associated world. At the point when the Salesforce1 World Tour landed in London a month ago, the keynote talks fortified the cloud, social, portable world the organization depicts. As cloud-first was portrayed as "the new mantra in today's reality" by COO George Hu, this is an alternate venture in that course.

Salesforce's association with Philips comes in the midst of an arrangement of different partnerships, most quite with Microsoft and HP. Cloud services are increasingly being utilized in the IT world. As per AMR’s research, cloud services market would reach $555 Billion globally by 2020. 

Major breakthrough in Bio Acrylic Acids

The combined efforts of acrylic acid market major players BASF, Cargill and Novozymes have yielded a significant breakthrough in techniques to produce bio acrylic acid. The team has succeeded in producing 3-hydroxypropionic acid (3-HP) in pilot scale, which can be used as an input chemical for producing acrylic acid. “3-HP is a potential key raw material for the production of bio-based acrylic acid which is a precursor of superabsorbent polymers,” stated Teressa Szelest, Senior Vice President Global Hygiene Business at BASF. “We still have a fair amount of work to do before the process is commercially ready, but this is a significant milestone and we are confident we can continue to the next level of scale-up for the entire process in 2014.”

Since acrylic acid is conventionally produced from fossil fuels, 3-HP, being a renewable and eco-friendly resource gives a fresh lease of life to this very useful product. This breakthrough has  decreased the restraints of acrylic acids in the global markets. “Our three companies have assembled highly talented and experienced joint working teams for this project,”  stated Jack Staloch, Vice President of Biotechnology R&D at Cargill. “They’ve moved with speed and intensity, and have demonstrated great progress toward accomplishing our goals.”

 “We have reached an important milestone by producing 3-HP in pilot scale,” said Rasmus von Gottberg, Vice President of Corporate Development and Business Creation at Novozymes. “We have shown that it is possible to make this key chemical building block from renewable raw materials in robust industrial conditions. Now the development work will continue towards commercialization.”

 Such efforts from leading producers are making the acrylic acid global market all the more lucrative. As per a latest study by Allied Market Research, the global acrylic acid market is poised to reach $22.78bn by 2020. Bio-acrylic acid certainly reinforces this claim, providing a sea of opportunities to the investors.

Friday, 27 June 2014

Hygienic robots gets the rating by D4

Codian Robotics of Veenendaal, Netherlands is satisfied to report accessibility of their new line of Ip69k evaluated Hygienic Robots for wash down applications along with its cleaning results. This group of robots is currently accessible in work cover sizes of 800 mm, 1100 mm, and 1300 mm. Extra sizes of 500 mm and 1600 mm will be accessible later in 2014.

The new D4 HD family emphasizes 316l Stainless Steel and Type 1 Titanium construction with a Viwateq finish, sealed motor/gearbox compartments,  watertight construction of pivot hub & primary body, and sealed cable gland.

Sealed compartments permit the utilization of standard gearboxes and motors, bringing down the expense of new parts, and permitting institutionalization of spares with our different robots in the D4 gang.

Their D4 HD conveys the same quick and calm execution, and the same open control system ability as alternate parts of the D2 and D4 robot families.


EEL Genome Sequencing to reveal numerous Secrets

Surprisingly, the genome of the electric eel has been sequenced. This finding has uncovered the mystery of how fish with electric organs have advanced six times in the historical backdrop of life to create electricity outside of their bodies.

"It's truly exciting to find that complex structures like the electric organ, which evolved completely independently in six groups of fish, seem to share the same genetic toolkit," said Jason Gallant, MSU zoologist and co-lead author of the paper. "Biologists are starting to learn, using genomics, that evolution makes similar structures from the same starting materials, even if the organisms aren't even that closely related."

The research, distributed in the ebb and flow issue of Science, sheds light on the hereditary outline used to advance these intricate, novel organs. It was co-headed by Michigan State University, University of Wisconsin-Madison, University of Texas-Austin and the Systemix Institute.

"Evolution has removed the ability of muscle cells to contract and changed the distribution of proteins in the cell membrane; now all electrocytes do is push ions across a membrane to create a massive flow of positive charge," said Lindsay Traeger, U-W graduate student and co-author of the study.

The "in-series alignment" of the electrocytes and unique polarity of each cell allows for the "summation of voltages, much like batteries stacked in series in a flashlight," said Michael Sussman, U-W biochemist.


The field of bioinformatics has grown tremendously with the realization of its true potential. The market would reach $12.86 billion, witha CAGR of 21.2%, by 2020, as per a report of Allied Market Research. We could await more exciting breakthroughs in the field of bioinformatics.

Rare coding variant can be tested with the help of KASP chemistry

LGC's exclusive KASP genotyping assay has been effectively contrasted with an option innovation for planning custom genotyping assays.

A group of heading researchers at the University of Nottingham did an immediate investigation of LGC's hand crafted KASP chemistry and existing Taqman genotyping assays, and found that utilizing KASP genotyping creates preferable comes about over different advances.

The study thought about the viability of the two innovations in effective configuration of custom genotyping assays for an uncommon toxic mis-sense coding variants recommended to have association with Alzheimer's ailment.

Through an unprejudiced methodology, genome-wide association studies (GWAS) have uncovered a lot new ailment hazard genes connected with complex issue, be that as it may, recognizing the useful variant straightforwardly included in a disease is more convoluted.

Immediate genotyping in replication case-and control-samples is frequently needed to affirm a variant's association with a given disease. It is thusly essential to have a solid genotyping assay accessible.

LGC KASP assays and reagents item supervisor Joris Parmentier said that the organization has streamlined its KASP assay plan algorithms and acceptance methods to guarantee that it can outline compelling assays for different varieties of hereditary variety, including uncommon variants.

"We work continuously to improve our chemistry and are proud that renowned academic centres such as the University of Nottingham find our KASP technology outperforms other genotyping methods in designing effective assays.

"These results show that our KASP technology is applicable in a variety of research applications. We remain proud that we continue to contribute to our customers' research by helping them find and validate the mutations responsible for human diseases," Parmentier added.


IVD is proving to be an effective technique in curing diseases. Thus, it is getting popular across the globe. As per the latest market research, the global IVD market is expected to reach $30.1 billion by 2020 growing at a CAGR of 4.02% during 2014-2020.

Monday, 23 June 2014

Application of synthetic biology in making soaps

The New York Times as of late uncovered that some soap organizations were supplanting the palm oil in their items with a substitute made by algae. The dubious part is that the yeast algae are genetically modified — they're the result of another branch known as synthetic biology.

In the New York Times piece, composed by Stephanie Strom, the organizations that were going for synthetic-biology-palm-oil substitutions reacted secretly to request — and the activists who had brought their work to light went about as though it were a despicable mystery.

“Palm oil has been such an extreme disaster for forests, and the environment more generally, that if these synthetic organisms can produce large volumes of vegetable oil, we should celebrate them,” said, Glenn Hurowitz, chair of the Forest Heroes Campaign.

“We wish every success toward the development of ultra-high-yield vegetable-oil technology,” Hurowitz said.
The issue is that synthetic biology is not developing enough to do that yet. As of now, the engineering is just practical for supplanting hard-to-get chemicals. Indeed, those chemicals may originate from palm oil, yet the sums are so little that there is no option have any kind of effect. The synthetic-biology organizations are still not at the phase where they can contend with shoddy, mass products like palm or soy oil — yet they're getting close.

“Essentially what they are doing is turning sugar cane to palm oil,” Hurowitz said. “They’re not breaking the link with conventional AG production.”

A few organizations out there are attempting to do simply that — they're starting to utilize synthetic biology to transform carbon dioxide and methane into vegetable oil and fuel. In any case, the work is still in the early stages. Therefore, palm-oil supplanting made with synthetic biology may be a genuine natural aid later on, however, it is not so yet.

Synthetic biology as a branch is growing leaps and bounds. A latest research projects the synthetic biology market to reach $38.7 billion by 2020. If this were the case, then global synthetic biology market would be a great investing opportunity for science and healthcare professionals.